Skip to content
mapperlab
← Dashboard
Stock

LYRA

Lyra Therapeutics, Inc.
0 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
0
27 funds tracked
Ever held
4
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

Aug 14, 2024Feb 14, 2025Nov 14, 2025Feb 17, 2026
Now
0

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Citadel Advisors 2× in & out+0%
Two Sigma Investments+0%
AQR Capital Management+0%
Millennium Management+0%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Lyra Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
1
Filings · last 90d
3
Total on file
111
Recent SEC buffer
Most recent
May 15, 2026

30d / 90d windows measured from May 15, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 111 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Lyra Therapeutics, Inc.

Annual figures sourced directly from Lyra Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$398K
FY2025-74% YoY
Net income
-$28.92M
FY2025+69% YoY
EPS (diluted)
$-18.62
FY2025+74% YoY
Free cash flow(?)
-$28.98M
FY2025+60% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Lyra Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ4 2025Q1 2026$0.00+0%
AQR Capital ManagementQ4 2024Q3 2025$0.00+0%
Citadel AdvisorsQ3 2024Q1 2025$0.00+0%
Two Sigma InvestmentsQ3 2024Q3 2025$0.00+0%
Millennium ManagementQ3 2024Q4 2024$0.00+0%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.